HIV-1 latency reversal agent boosting is not limited by opioid use

Tyler Lilie, Jennifer Bouzy, Archana Asundi, Jessica Taylor, Samantha Roche, Alex Olson, Kendyll Coxen, Heather Corry, Hannah Jordan, Kiera Clayton, Nina Lin, Athe Tsibris
doi: https://doi.org/10.1101/2023.05.26.23290576

Article Information

doi 
https://doi.org/10.1101/2023.05.26.23290576
History 
  • June 4, 2024.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Tyler Lilie1,†,
  2. Jennifer Bouzy1,†,
  3. Archana Asundi2,
  4. Jessica Taylor2,3,
  5. Samantha Roche2,
  6. Alex Olson2,
  7. Kendyll Coxen1,
  8. Heather Corry1,
  9. Hannah Jordan1,
  10. Kiera Clayton4,
  11. Nina Lin2,‡ and
  12. Athe Tsibris1,5,‡,*
  1. 1Brigham and Women’s Hospital, Boston, MA, USA
  2. 2Department of Medicine, Boston University School of Medicine & Boston Medical Center, Boston, MA USA
  3. 3Grayken Center for Addiction, Boston Medical Center, Boston, MA USA
  4. 4Department of Pathology, University of Massachusetts T.H. Chan School of Medicine, Worcester, MA, USA
  5. 5Harvard Medical School, Boston, MA, USA
  1. ↵*Correspondence: atsibris{at}bwh.harvard.edu

  1. ↵† These authors contributed equally to this work

  2. ↵‡ These authors contributed equally to this work

Back to top
Posted June 04, 2024.
Download PDF

Supplementary Material

Data/Code
Email
HIV-1 latency reversal agent boosting is not limited by opioid use
Tyler Lilie, Jennifer Bouzy, Archana Asundi, Jessica Taylor, Samantha Roche, Alex Olson, Kendyll Coxen, Heather Corry, Hannah Jordan, Kiera Clayton, Nina Lin, Athe Tsibris
medRxiv 2023.05.26.23290576; doi: https://doi.org/10.1101/2023.05.26.23290576
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area